Nathan Herrmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2049113/publications.pdf

Version: 2024-02-01

235 papers 8,157 citations

50170 46 h-index 78 g-index

250 all docs

250 docs citations

times ranked

250

10808 citing authors

#	Article	IF	CITATIONS
1	Blood–brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound. Nature Communications, 2018, 9, 2336.	5.8	618
2	Peripheral inflammatory markers in Alzheimer's disease: a systematic review and meta-analysis of 175 studies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 876-882.	0.9	336
3	The Mild Behavioral Impairment ChecklistÂ(MBI-C): A Rating Scale forÂNeuropsychiatric Symptoms inÂPre-Dementia Populations. Journal of Alzheimer's Disease, 2017, 56, 929-938.	1.2	306
4	Identification of Physician-Diagnosed Alzheimer's Disease and Related Dementias in Population-Based Administrative Data: A Validation Study Using Family Physicians' Electronic Medical Records. Journal of Alzheimer's Disease, 2016, 54, 337-349.	1.2	200
5	Current and Emerging Drug Treatment Options for Alzheimer's Disease. Drugs, 2011, 71, 2031-2065.	4.9	196
6	The contribution of neuropsychiatric symptoms to the cost of dementia care. International Journal of Geriatric Psychiatry, 2006, 21, 972-976.	1.3	190
7	Functional and Neuroanatomic Correlations in Poststroke Depression. Stroke, 2000, 31, 637-644.	1.0	185
8	IPA survey of brief cognitive screening instruments. International Psychogeriatrics, 2006, 18, 281-294.	0.6	172
9	A validation study of The Geriatric Depression Scale short form. International Journal of Geriatric Psychiatry, 1996, 11, 457-460.	1.3	157
10	Autobiographical episodic memory in major depressive disorder Journal of Abnormal Psychology, 2014, 123, 51-60.	2.0	152
11	Do Atypical Antipsychotics Cause Stroke?. CNS Drugs, 2005, 19, 91-103.	2.7	143
12	Methylphenidate for the Treatment of Apathy in Alzheimer Disease. Journal of Clinical Psychopharmacology, 2008, 28, 296-301.	0.7	124
13	Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. Alzheimer's and Dementia, 2020, 16, 1182-1195.	0.4	119
14	Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis. Scientific Reports, 2018, 8, 5804.	1.6	118
15	"Good Outcome―Isn't Good Enough. Stroke, 2017, 48, 1688-1690.	1.0	116
16	Theta-Gamma Coupling and Working Memory in Alzheimer's Dementia and Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2018, 10, 101.	1.7	103
17	Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders. Translational Psychiatry, 2020, 10, 152.	2.4	102
18	Role of Serotonin in the Behavioral and Psychological Symptoms of Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 2001, 13, 5-21.	0.9	98

#	Article	IF	CITATIONS
19	Serotonergic Function and Treatment of Behavioral and Psychological Symptoms of Frontotemporal Dementia. American Journal of Geriatric Psychiatry, 2012, 20, 789-797.	0.6	97
20	The Role of Norepinephrine in the Behavioral and Psychological Symptoms of Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 2004, 16, 261-276.	0.9	93
21	Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease. American Journal of Geriatric Psychiatry, 2019, 27, 1161-1173.	0.6	90
22	The Importance of Lesion Location in Poststroke Depression: A Critical Review. Canadian Journal of Psychiatry, 1998, 43, 921-927.	0.9	88
23	<i>Canadianâ€Strokeâ€Bestâ€Practiceâ€Recommendations: Mood, Cognition and Fatigue following Stro Practice Guidelines, Update 2015. International Journal of Stroke, 2015, 10, 1130-1140.</i>	ke	88
24	Donepezil for behavioural disorders associated with Lewy bodies: a case series., 2000, 15, 338-345.		86
25	A Placebo-Controlled Trial of Valproate for Agitation and Aggression in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2007, 23, 116-119.	0.7	82
26	Recommendations for the Management of Behavioral and Psychological Symptoms of Dementia. Canadian Journal of Neurological Sciences, 2001, 28, S96-S107.	0.3	81
27	Post-stroke depression, obstructive sleep apnea, and cognitive impairment: Rationale for, and barriers to, routine screening. International Journal of Stroke, 2016, 11, 509-518.	2.9	81
28	Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo*. Clinical Pharmacology and Therapeutics, 1997, 62, 334-347.	2.3	80
29	The Interplay Between Post-traumatic Stress Disorder and Dementia: A Systematic Review. American Journal of Geriatric Psychiatry, 2020, 28, 48-60.	0.6	79
30	READMIT: A clinical risk index to predict 30-day readmission after discharge from acute psychiatric units. Journal of Psychiatric Research, 2015, 61, 205-213.	1.5	74
31	Predictors of driving cessation in mild-to-moderate dementia. Cmaj, 2006, 175, 591-595.	0.9	72
32	Trends in Psychotropic Dispensing Among Older Adults with Dementia Living inÂLong-Term Care Facilities: 2004–2013. American Journal of Geriatric Psychiatry, 2015, 23, 1259-1269.	0.6	72
33	A Populationâ€Based Study of Cholinesterase Inhibitor Use for Dementia. Journal of the American Geriatrics Society, 2007, 55, 1517-1523.	1.3	66
34	Challenges of conducting research in long-term care facilities: a systematic review. BMC Geriatrics, 2018, 18, 242.	1.1	66
35	Ceramides and depression: A systematic review. Journal of Affective Disorders, 2017, 213, 35-43.	2.0	64
36	Valproic Acid Treatment of Agitation in Dementia. Canadian Journal of Psychiatry, 1998, 43, 69-72.	0.9	63

3

#	Article	IF	CITATIONS
37	Pharmacologic Management of Neuropsychiatric Symptoms of Alzheimer Disease. Canadian Journal of Psychiatry, 2007, 52, 630-646.	0.9	62
38	Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. Medical Journal of Australia, 2019, 210, 174-179.	0.8	61
39	The Roles of Apathy and Depression in Predicting Alzheimer Disease: A Longitudinal Analysis in Older Adults With Mild Cognitive Impairment. American Journal of Geriatric Psychiatry, 2019, 27, 873-882.	0.6	61
40	Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. American Journal of Geriatric Psychiatry, 2005, 13, 527-34.	0.6	58
41	Factor Analysis of the Rivermead Post-Concussion Symptoms Questionnaire in Mild-to-Moderate Traumatic Brain Injury Patients. Journal of Neuropsychiatry and Clinical Neurosciences, 2009, 21, 181-188.	0.9	57
42	Global grey matter volume in adult bipolar patients with and without lithium treatment: A meta-analysis. Journal of Affective Disorders, 2018, 225, 599-606.	2.0	55
43	Memantine in dementia: a review of the current evidence. Expert Opinion on Pharmacotherapy, 2011, 12, 787-800.	0.9	53
44	Clinical practice guidelines for severe Alzheimer's disease. Alzheimer's and Dementia, 2007, 3, 385-397.	0.4	51
45	A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease. International Psychogeriatrics, 2013, 25, 919-927.	0.6	51
46	Inflammatory Markers in Mild Cognitive Impairment: A Meta-Analysis. Journal of Alzheimer's Disease, 2015, 47, 669-679.	1.2	49
47	White Matter Microstructural Integrity Is Associated with Executive Function and Processing Speed in Older Adults with Coronary Artery Disease. American Journal of Geriatric Psychiatry, 2015, 23, 754-763.	0.6	49
48	The use of non-prescription sleep products in the elderly. International Journal of Geriatric Psychiatry, 1999, 14, 851-857.	1.3	48
49	Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease. CNS Drugs, 2015, 29, 615-623.	2.7	47
50	A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease. Journal of the American Medical Directors Association, 2016, 17, 142-147.	1.2	47
51	A meta-analysis of lipid peroxidation markers in major depression. Neuropsychiatric Disease and Treatment, 2015, 11, 2479.	1.0	44
52	Brief Mindfulness Meditation for Depression and Anxiety Symptoms in Patients Undergoing Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 2008-2015.	2.2	43
53	Central Serotonergic Activity is Related to the Aggressive Behaviors of Alzheimer's Disease. Neuropsychopharmacology, 2002, 27, 646-54.	2.8	42
54	Changing Pattern of Sedative Use in Older Adults: A Population-Based Cohort Study. Drugs and Aging, 2016, 33, 523-533.	1.3	42

#	Article	IF	CITATIONS
55	Screening for Post-Stroke Depression and Cognitive Impairment at Baseline Predicts Long-Term Patient-Centered Outcomes After Stroke. Journal of Geriatric Psychiatry and Neurology, 2019, 32, 40-48.	1.2	42
56	Atypical Antipsychotics for Neuropsychiatric Symptoms of Dementia. Drug Safety, 2006, 29, 833-843.	1.4	40
57	Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial. International Psychogeriatrics, 2014, 26, 239-246.	0.6	40
58	<i>APOE</i> â€îµ4 associates with hippocampal volume, learning, and memory across the spectrum of Alzheimer's disease and dementia with Lewy bodies. Alzheimer's and Dementia, 2018, 14, 1137-1147.	0.4	39
59	Sharing the responsibility for assessing the risk of the driver with dementia. Cmaj, 2007, 177, 599-601.	0.9	38
60	Update on the Risk of Motor Vehicle Collision or Driving Impairment with Dementia: A Collaborative International Systematic Review and Meta-Analysis. American Journal of Geriatric Psychiatry, 2017, 25, 1376-1390.	0.6	38
61	Delphi survey of maintenance lithium treatment in older adults with bipolar disorder: An ISBD task force report. Bipolar Disorders, 2019, 21, 117-123.	1.1	38
62	Persistence with Cholinesterase Inhibitor Therapy for Dementia. Drugs and Aging, 2009, 26, 403-407.	1.3	36
63	The Times They Are a-Changin'. Journal of Geriatric Psychiatry and Neurology, 2015, 28, 145-155.	1.2	35
64	Exercise for Cognitive Symptoms in Depression: A Systematic Review of Interventional Studies. Canadian Journal of Psychiatry, 2018, 63, 115-128.	0.9	34
65	The effect of exercise on resting concentrations of peripheral brain-derived neurotrophic factor (BDNF) in major depressive disorder: A meta-analysis. Journal of Psychiatric Research, 2018, 105, 123-131.	1.5	34
66	Efficacy of non-invasive brain stimulation on global cognition and neuropsychiatric symptoms in Alzheimer's disease and mild cognitive impairment: A meta-analysis and systematic review. Ageing Research Reviews, 2021, 72, 101499.	5.0	34
67	Behavioural Disturbances in the Demented Elderly: Phenomenology, Pharmacotherapy and Behavioural Management [*] . Canadian Journal of Psychiatry, 1992, 37, 651-657.	0.9	33
68	Does Pharmacological Treatment of Neuropsychiatric Symptoms in Alzheimer $\hat{E}\frac{1}{4}$ s Disease Relieve Caregiver Burden?. Drugs and Aging, 2012, 29, 167-179.	1.3	33
69	Prevalence and Correlates of Renal Disease in Older Lithium Users: A Population-Based Study. American Journal of Geriatric Psychiatry, 2014, 22, 1075-1082.	0.6	32
70	National Dementia Strategies: What Should Canada Learn?. Canadian Geriatrics Journal, 2018, 21, 173-209.	0.7	32
71	Lithium Use in Older Adults is Associated with Increased Prescribing of Parkinson Medications. American Journal of Geriatric Psychiatry, 2016, 24, 301-309.	0.6	31
72	Lowâ€Dose Trazodone, Benzodiazepines, and Fallâ€Related Injuries in Nursing Homes: A Matchedâ€Cohort Study. Journal of the American Geriatrics Society, 2018, 66, 1963-1971.	1.3	31

#	Article	IF	Citations
73	Biomarkers of agitation and aggression in Alzheimer's disease: A systematic review. , 2018, 14, 1344-1376.		31
74	The association between cognitive fluctuations and activities of daily living and quality of life among institutionalized patients with dementia. International Journal of Geriatric Psychiatry, 2018, 33, e280-e285.	1.3	29
75	The Relation between Disease Severity and Cost of Caring for Patients with Alzheimer Disease in Canada. Canadian Journal of Psychiatry, 2010, 55, 768-775.	0.9	28
76	Use of Medications of Questionable Benefit at the End of Life in Nursing Home Residents with Advanced Dementia. Journal of the American Geriatrics Society, 2017, 65, 1535-1542.	1.3	28
77	Peripheral lipid oxidative stress markers are related to vascular risk factors and subcortical small vessel disease. Neurobiology of Aging, 2017, 59, 91-97.	1.5	28
78	Mild behavioral impairment is associated with progression to Alzheimer's disease: A clinicopathological study. Alzheimer's and Dementia, 2022, 18, 2199-2208.	0.4	28
79	Exploring Visual Selective Attention towards Novel Stimuli in Alzheimer's Disease Patients. Dementia and Geriatric Cognitive Disorders Extra, 2015, 5, 492-502.	0.6	27
80	Pain assessment tools for older adults with dementia in long-term care facilities: a systematic review. Neurodegenerative Disease Management, 2016, 6, 525-538.	1.2	27
81	Design and Rationale of the PACt-MD Randomized Clinical Trial: Prevention of Alzheimer's dementia with Cognitive remediation plus transcranial direct current stimulation in Mild cognitive impairment and Depression. Journal of Alzheimer's Disease, 2020, 76, 733-751.	1.2	27
82	Changes in Nursing Burden Following Memantine for Agitation and Aggression in Long-Term Care Residents with Moderate to Severe Alzheimer $\hat{E}^{1}\!\!/\!\!4$ s Disease. CNS Drugs, 2011, 25, 425-433.	2.7	26
83	<p>The value of screening for cognition, depression, and frailty in patients referred for TAVI</p> . Clinical Interventions in Aging, 2019, Volume 14, 841-848.	1.3	26
84	The use of clock tests in schizophrenia. General Hospital Psychiatry, 1999, 21, 70-73.	1.2	25
85	Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts. International Psychogeriatrics, 2011, 23, 539-545.	0.6	25
86	Oxidative stress predicts depressive symptom changes with omega-3 fatty acid treatment in coronary artery disease patients. Brain, Behavior, and Immunity, 2017, 60, 136-141.	2.0	25
87	Assessing Capacity in the Elderly: Comparing the MoCA with a Novel Computerized Battery of Executive Function. Dementia and Geriatric Cognitive Disorders Extra, 2017, 7, 249-256.	0.6	25
88	Natural and Synthetic Cannabinoids for Agitation and Aggression in Alzheimer's Disease. Journal of Clinical Psychiatry, 2019, 80, .	1.1	25
89	C-reactive protein and cardiovascular risk in bipolar disorder patients: A systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 79, 442-451.	2.5	24
90	Lithium Toxicity in Older Adults: a Systematic Review of Case Reports. Clinical Drug Investigation, 2018, 38, 201-209.	1.1	24

#	Article	IF	CITATIONS
91	Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia. Drugs and Aging, 2019, 36, 589-605.	1.3	24
92	Younger Age and Depressive Symptoms Predict High Risk of Generalized Anxiety After Stroke and Transient Ischemic Attack. Stroke, 2019, 50, 2359-2363.	1.0	23
93	Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation. Journal of Geriatric Psychiatry and Neurology, 2020, 33, 175-184.	1.2	23
94	Current psychotropic medication prescribing patterns in lateâ€life bipolar disorder. International Journal of Geriatric Psychiatry, 2017, 32, 1459-1465.	1.3	22
95	An International Approach to Enhancing a National Guideline on Driving and Dementia. Current Psychiatry Reports, 2018, 20, 16.	2.1	22
96	Predicting psychiatric readmission: sex-specific models to predict 30-day readmission following acute psychiatric hospitalization. Social Psychiatry and Psychiatric Epidemiology, 2018, 53, 139-149.	1.6	22
97	Neutrophil activation in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis of protein markers in blood and cerebrospinal fluid. Ageing Research Reviews, 2020, 62, 101130.	5.0	22
98	Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Neurobiology of Aging, 2021, 100, 22-31.	1.5	22
99	Growth hormone response to clonidine predicts aggression in Alzheimer's disease. Psychoneuroendocrinology, 2004, 29, 1192-1197.	1.3	21
100	Kynurenine and depressive symptoms in a poststroke population. Neuropsychiatric Disease and Treatment, 2014, 10, 1827.	1.0	21
101	Therapeutic trial design for frontotemporal dementia and related disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 412-423.	0.9	21
102	Prevalence of Antidepressant Use Among Older People: Populationâ€Based Observations. Journal of the American Geriatrics Society, 1999, 47, 1350-1353.	1.3	20
103	Developing Physician Consensus on the Reporting of Patients with Mild Cognitive Impairment and Mild Dementia to Transportation Authorities in a Region with Mandatory Reporting Legislation. American Journal of Geriatric Psychiatry, 2014, 22, 1530-1543.	0.6	20
104	Validating a Pragmatic Approach to Cognitive Screening in Stroke Prevention Clinics Using the Montreal Cognitive Assessment. Stroke, 2016, 47, 807-813.	1.0	20
105	Suicide in males and females with cardiovascular disease and comorbid depression. Journal of Affective Disorders, 2016, 197, 88-93.	2.0	20
106	Comparison of prescribing practices for older adults treated by female versus male physicians: A retrospective cohort study. PLoS ONE, 2018, 13, e0205524.	1.1	20
107	Assessing Cognitive Effects of Anticholinergic Medications in Patients With Coronary Artery Disease. Psychosomatics, 2014, 55, 61-68.	2.5	19
108	Can clock drawing differentiate Alzheimer's disease from other dementias?. International Psychogeriatrics, 2015, 27, 1649-1660.	0.6	19

#	Article	IF	CITATIONS
109	Cognitive Outcomes following Transcatheter Aortic Valve Implantation: A Systematic Review. Cardiovascular Psychiatry and Neurology, 2015, 2015, 1-8.	0.8	19
110	Apathy, not depressive symptoms, as a predictor of semantic and phonemic fluency task performance in stroke and transient ischemic attack. Journal of Clinical and Experimental Neuropsychology, 2018, 40, 449-461.	0.8	19
111	Theta–gamma coupling and ordering information: a stable brain–behavior relationship across cognitive tasks and clinical conditions. Neuropsychopharmacology, 2020, 45, 2038-2047.	2.8	19
112	Cardiopulmonary Fitness Correlates with Regional Cerebral Grey Matter Perfusion and Density in Men with Coronary Artery Disease. PLoS ONE, 2014, 9, e91251.	1,1	18
113	Molecular mechanisms in lithium-associated renal disease: a systematic review. International Urology and Nephrology, 2016, 48, 1843-1853.	0.6	18
114	Systematic Review of Sexâ€Specific Reporting of Data: Cholinesterase Inhibitor Example. Journal of the American Geriatrics Society, 2017, 65, 2213-2219.	1.3	18
115	Risk Factors for Progression of Alzheimer Disease in a Canadian Population: The Canadian Outcomes Study in Dementia (COSID). Canadian Journal of Psychiatry, 2015, 60, 189-199.	0.9	17
116	Medical comorbidity, acute medical care use in late-life bipolar disorder: a comparison of lithium, valproate, and other pharmacotherapies. General Hospital Psychiatry, 2015, 37, 528-532.	1.2	17
117	A Lipidomics Approach to Assess theÂAssociation Between Plasma Sphingolipids and Verbal Memory Performance in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation: A C18:0 Signature forÂCognitive Response to Exercise. Journal of Alzheimer's Disease, 2017, 60, 829-841.	1.2	17
118	Association of Lithium Use and a Higher Serum Concentration of Lithium With the Risk of Declining Renal Function in Older Adults. Journal of Clinical Psychiatry, 2020, 81, .	1.1	17
119	Validity of the Center for Epidemiological Studies Depression scale in Type 2 diabetes. Journal of Psychosomatic Research, 2016, 90, 91-97.	1.2	16
120	Changes in Theta but not Alpha Modulation Are Associated with Impairment in Working Memory in Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 68, 1085-1094.	1.2	16
121	Association Between Sphingolipids and Cardiopulmonary Fitness in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 671-679.	1.7	16
122	Depression in type 2 diabetes: A systematic review and meta-analysis of blood inflammatory markers. Psychoneuroendocrinology, 2021, 134, 105448.	1.3	16
123	Distraction adds to the cognitive burden in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 106-113.	1.4	15
124	The Role of Apathy and Depression on Verbal Learning and Memory Performance After Stroke. Archives of Clinical Neuropsychology, 2019, 34, 327-336.	0.3	15
125	Symptoms of depression and cognitive impairment in young adults after stroke/transient ischemic attack. Psychiatry Research, 2019, 279, 361-363.	1.7	15
126	A Case for the Standardized Assessment of Testamentary Capacity. Canadian Geriatrics Journal, 2018, 21, 26-31.	0.7	15

#	Article	IF	CITATIONS
127	Cognitive Pharmacotherapy of Alzheimer's Disease and other Dementias. Canadian Journal of Psychiatry, 2002, 47, 715-722.	0.9	14
128	Detection and treatment of post stroke depression: results from the registry of the Canadian stroke network. International Journal of Geriatric Psychiatry, 2011, 26, 1195-1200.	1.3	14
129	Lipid Peroxidation Markers in Coronary Artery Disease Patients with Possible Vascular Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 58, 885-896.	1.2	14
130	Predictors of Cholinesterase Discontinuation during the First Year after Nursing Home Admission. Journal of the American Medical Directors Association, 2018, 19, 959-966.e4.	1.2	14
131	The effect of atorvastatin on cognition and mood in bipolar disorder and unipolar depression patients: A secondary analysis of a randomized controlled trial. Journal of Affective Disorders, 2020, 262, 149-154.	2.0	14
132	Frontal-executive and corticolimbic structural brain circuitry in older people with remitted depression, mild cognitive impairment, Alzheimer's dementia, and normal cognition. Neuropsychopharmacology, 2020, 45, 1567-1578.	2.8	14
133	Serum soluble epoxide hydrolase related oxylipins and major depression in patients with type 2 diabetes. Psychoneuroendocrinology, 2021, 126, 105149.	1.3	14
134	Platelet activating factors are associated with depressive symptoms in coronary artery disease patients: a hypothesis-generating study. Neuropsychiatric Disease and Treatment, 2015, 11, 2309.	1.0	13
135	Development of a decision-making tool for reporting drivers with mild dementia and mild cognitive impairment to transportation administrators. International Psychogeriatrics, 2017, 29, 1551-1563.	0.6	13
136	Depression and Increased Risk of Alzheimer's Dementia: Longitudinal Analyses of Modifiable Risk and Sex-Related Factors. American Journal of Geriatric Psychiatry, 2021, 29, 917-926.	0.6	13
137	Lithium Use, but Not Valproate Use, Is Associated With a Higher Risk of Chronic Kidney Disease in Older Adults With Mental Illness. Journal of Clinical Psychiatry, 2017, 78, e980-e985.	1.1	13
138	Posttraumatic Stress Disorder in Institutionalized World War II Veterans. American Journal of Geriatric Psychiatry, 1994, 2, 324-331.	0.6	12
139	Persistence of Antipsychotic Treatment in Elderly Dementia Patients: A Retrospective, Population-Based Cohort Study. Drugs - Real World Outcomes, 2016, 3, 175-182.	0.7	12
140	Correlates of nursing care burden among institutionalized patients with dementia. International Psychogeriatrics, 2018, 30, 1549-1555.	0.6	12
141	24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone. Journal of Alzheimer's Disease, 2019, 71, 21-31.	1.2	12
142	Diagnostic Precision in the Detection of Mild Cognitive Impairment: A Comparison of Two Approaches. American Journal of Geriatric Psychiatry, 2022, 30, 54-64.	0.6	12
143	Drugs Mimicking Dementia. CNS Drugs, 2000, 14, 381-390.	2.7	11
144	Initial Cholinesterase Inhibitor Therapy Dose and Serious Events in Older Women and Men. Journal of the American Geriatrics Society, 2018, 66, 1692-1699.	1.3	11

#	Article	IF	Citations
145	Association between Sleep Disturbances and Medial Temporal Lobe Volume in Older Adults with Mild Cognitive Impairment Free of Lifetime History of Depression. Journal of Alzheimer's Disease, 2019, 69, 413-421.	1.2	11
146	Validity of the QUADAS-2 in Assessing Risk of Bias in Alzheimer's Disease Diagnostic Accuracy Studies. Frontiers in Psychiatry, 2018, 9, 221.	1.3	10
147	Centre- versus home-based exercise among people with mci and mild dementia: study protocol for a randomized parallel-group trial. BMC Geriatrics, 2018, 18, 27.	1.1	10
148	Is Cardiac Rehabilitation Exercise Feasible for People with Mild Cognitive Impairment?. Canadian Geriatrics Journal, 2015, 18, 65-72.	0.7	10
149	Cognitive Fluctuations and the Lucid Interval in Dementia: Implications for Testamentary Capacity. Journal of the American Academy of Psychiatry and the Law, 2015, 43, 287-92.	0.2	10
150	Lithium augmentation in geriatric depressed outpatients: A clinical report. International Journal of Geriatric Psychiatry, 1994, 9, 995-1002.	1.3	9
151	Treatment of Moderate to Severe Alzheimer's Disease: Rationale and Trial Design. Canadian Journal of Neurological Sciences, 2007, 34, S103-S108.	0.3	9
152	Examining the Link Between Cardiovascular Risk Factors and Neuropsychiatric Symptoms in Mild Cognitive Impairment and Major Depressive Disorder in Remission. Journal of Alzheimer's Disease, 2019, 67, 1305-1311.	1.2	9
153	Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer's Disease Dementia: Findings from the Ontario Neurodegenerative Disease Research Initiative (ONDRI) Study and Clinical Trials Over the Past 10 Years. Journal of Alzheimer's Disease, 2020, 74, 747-757.	1.2	9
154	Functional Connectivity Between the Posterior Default Mode Network and Parahippocampal Gyrus Is Disrupted in Older Adults with Subjective Cognitive Decline and Correlates with Subjective Memory Ability. Journal of Alzheimer's Disease, 2021, 82, 435-445.	1.2	9
155	Serum low-density lipoprotein levels, statin use, and cognition in patients with coronary artery disease. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 2913-2920.	1.0	8
156	Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment ofÂAlzheimer's Disease. Journal of Alzheimer's Disease, 2016, 54, 373-381.	1.2	8
157	Omega-3/omega-6 fatty acid ratios in different phospholipid classes and depressive symptoms in coronary artery disease patients. Brain, Behavior, and Immunity, 2016, 53, 54-58.	2.0	8
158	Baseline Oxidative Stress Is Associated with Memory Changes in Omega-3 Fatty Acid Treated Coronary Artery Disease Patients. Cardiovascular Psychiatry and Neurology, 2017, 2017, 1-7.	0.8	8
159	Psychometric properties of apathy scales in Parkinson's disease: a systematic review. Neurodegenerative Disease Management, 2018, 8, 267-282.	1.2	8
160	Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial. BMC Psychiatry, 2018, 18, 227.	1.1	8
161	Clock drawing and neuroanatomical correlates: A systematic review. International Journal of Geriatric Psychiatry, 2019, 34, 223-232.	1.3	8
162	Prefrontal GABA Levels Correlate with Memory in Older Adults at High Risk for Alzheimer's Disease. Cerebral Cortex Communications, 2020, 1, tgaa022.	0.7	8

#	Article	IF	CITATIONS
163	Blood-based biomarkers of agitation in Alzheimer's disease: Advances and future prospects. Neurochemistry International, 2022, 152, 105250.	1.9	8
164	Endosomal-Lysosomal and Autophagy Pathway in Alzheimer's Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2022, 88, 1279-1292.	1.2	8
165	Determination of Financial Competence in Consultation-Liaison Psychiatry. Canadian Journal of Psychiatry, 1993, 38, 595-598.	0.9	7
166	Reply to: Serum Zinc and the Risk of Depression in Men: Observations from a 20-Year Follow-up Study. Biological Psychiatry, 2015, 77, e13-e14.	0.7	7
167	Suicide deaths by intentional self-poisoning in people with cardiovascular disease. General Hospital Psychiatry, 2018, 52, 41-47.	1.2	7
168	Longitudinal associations between 4-hydroxynonenal and depression in coronary artery disease patients. Psychiatry Research, 2018, 270, 219-224.	1.7	7
169	Piloting the global capacity education e-tool: can capacity be taught to health care professionals across different international jurisdictions?. International Psychogeriatrics, 2021, 33, 913-916.	0.6	7
170	A doubleâ€blind, randomized, placeboâ€controlled pilot trial of atorvastatin for nephrogenic diabetes insipidus in lithium users. Bipolar Disorders, 2021, 23, 66-75.	1.1	7
171	Management of Neuropsychiatric Symptoms in Long-Term Care Residents with Parkinson's Disease. Drugs and Aging, 2013, 30, 19-22.	1.3	6
172	Long-term effects of lithium on renal function. Lancet, The, 2015, 386, 1943-1944.	6.3	6
173	Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment. Journal of Neuroimaging, 2019, 29, 721-729.	1.0	6
174	Endostatin as a Mediator Between Endothelial Function and Cognitive Performance in Those at Risk for Vascular Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 76, 1-11.	1.2	6
175	Computer-Based Driving in Dementia Decision Tool With Mail Support: Cluster Randomized Controlled Trial. Journal of Medical Internet Research, 2018, 20, e194.	2.1	6
176	Abuse of Prescription and Licit Psychoactive Substances by the Elderly. CNS Drugs, 1995, 4, 207-221.	2.7	5
177	Age representation in antiepileptic drug trials: A systematic review and meta-analysis. Epilepsy Research, 2018, 142, 9-15.	0.8	5
178	Sex Differences in the Prevalent Use of Oral Formulations of Cholinesterase Inhibitors in Older Adults with Dementia. Drugs and Aging, 2019, 36, 875-884.	1.3	5
179	Validity of a novel screen for cognitive impairment and neuropsychiatric symptoms in cardiac rehabilitation. BMC Geriatrics, 2019, 19, 163.	1.1	5
180	Lifetime Alcohol Abuse in Institutionalized World War II Veterans. American Journal of Geriatric Psychiatry, 1996, 4, 39-45.	0.6	5

#	Article	IF	Citations
181	Physician Sex Is a Predictor of Reporting Drivers with Mild Cognitive Impairment and Mild Dementia to Transportation Authorities. Journal of the American Geriatrics Society, 2014, 62, 201-203.	1.3	4
182	Cognitive Fluctuations and Cognitive Test Performance Among Institutionalized Persons With Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2017, 32, 393-400.	0.9	4
183	The Role of the Medical Expert in the Retrospective Assessment of Testamentary Capacity. Canadian Journal of Psychiatry, 2021, 66, 255-261.	0.9	4
184	Assessing the Longitudinal Relationship between Theta-Gamma Coupling and Working Memory Performance in Older Adults. Cerebral Cortex, 2022, 32, 1653-1667.	1.6	4
185	Effects of Gender and Age on Phenomenology and Management of Bipolar Disorder. , 0, , 359-440.		4
186	Mandatory Training in Geriatric Psychiatry: Can Programs Deliver the Goods?. Canadian Journal of Psychiatry, 1994, 39, 523-525.	0.9	3
187	Some psychosocial therapies may reduce depression, aggression, or apathy in people with dementia. Evidence-Based Mental Health, 2005, 8, 104-104.	2.2	3
188	Distractibility in multiple sclerosis: The role of depression. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731665315.	0.5	3
189	Cholinesterase Inhibitor Discontinuation: The Buck Stops Here. American Journal of Geriatric Psychiatry, 2018, 26, 148-149.	0.6	3
190	Optimal use of cholinergic drugs in Alzheimer's disease. Brain, 2018, 141, e68.	3.7	3
191	Relationships Between a New Cultured Cell-Based Serum Anticholinergic Activity Assay and Anticholinergic Burden Scales or Cognitive Performance in Older Adults. American Journal of Geriatric Psychiatry, 2021, 29, 1239-1252.	0.6	3
192	Blood Lithium Monitoring Practices in a Population-Based Sample of Older Adults. Journal of Clinical Psychiatry, 2018, 79, .	1.1	3
193	Time setting errors in the Clock Drawing Test are associated with both semantic and executive deficits. Applied Neuropsychology Adult, 2022, , 1-10.	0.7	3
194	Association of functional connectivity of the executive control network or default mode network with cognitive impairment in older adults with remitted major depressive disorder or mild cognitive impairment. Neuropsychopharmacology, 2023, 48, 468-477.	2.8	3
195	Future Directions for Geriatric Anesthesiology. Anesthesiology Clinics, 2019, 37, 581-592.	0.6	2
196	A virtual second opinion: Acceptability of a computer-based decision tool to assess older drivers with dementia. Health Informatics Journal, 2020, 26, 911-924.	1.1	2
197	Serum osteocalcin is associated with subjective stress in people with depression and type 2 diabetes. Psychoneuroendocrinology, 2020, 122, 104878.	1.3	2
198	Functional Competence and Cognition in Individuals With Amnestic Mild Cognitive Impairment. Journal of the American Geriatrics Society, 2020, 68, 1787-1795.	1.3	2

#	Article	IF	Citations
199	Comparing cardiovascular risk factors in older persons with mild cognitive impairment and lifetime history of major depressive disorder. International Psychogeriatrics, 2021, , 1-7.	0.6	2
200	A validation study of The Geriatric Depression Scale short form. , 1996, 11, 457.		2
201	Mindfulness-Based Cognitive Therapy in the Treatment of Late-Life Anxiety and Depression —a Pilot Study. Canadian Geriatrics Journal, 2016, 19, 127-128.	0.7	2
202	An update on the neuropsychiatric symptoms of dementia. Neurodegenerative Disease Management, 2011, 1, 335-340.	1.2	1
203	P2-095: Predictors of worsening following cholinesterase inhibitor discontinuation trial in institutionalized persons with moderate to severe Alzheimer's disease: Results of a double-blind, placebo controlled trial., 2015, 11, P520-P520.		1
204	Relationships between oral hypoglycemic drugs and memory decline in people with type 2 diabetes: A stratified longitudinal observational study. Alzheimer's and Dementia, 2020, 16, e041312.	0.4	1
205	A validation study of The Geriatric Depression Scale short form. , 1996, 11, 457.		1
206	Emotion regulation in mild cognitive impairment and subjective cognitive decline. Alzheimer's and Dementia, 2021, 17 , .	0.4	1
207	Cognitive control, interference inhibition, and ordering of information during working memory in younger and older healthy adults. GeroScience, 2022, 44, 2291-2303.	2.1	1
208	Demystifying Psychiatric Research: Use of a Simulation. Academic Psychiatry, 1995, 19, 108-109.	0.4	0
209	Outcomes of Cognitive Fluctuations in Dementia Patients. Journal of the American Geriatrics Society, 2015, 63, 1258-1260.	1.3	0
210	P3â€200: Cognitive Outcomes Following Transcatheter Aortic Valve Implantation (TAVI). Alzheimer's and Dementia, 2016, 12, P899.	0.4	0
211	P1â€190: The Association Between Endothelial Dysfunction and Memory Performance in Patients With Coronary Artery Disease Undertaking Cardiac Rehabilitation. Alzheimer's and Dementia, 2016, 12, P476.	0.4	0
212	P1â€371: The Association Between Apathy and Executive Function in Coronary Artery Disease Patients is Modified By Endothelial Dysfunction. Alzheimer's and Dementia, 2016, 12, P573.	0.4	0
213	P2â€376: A Driving in Dementia Decision Tool: Preliminary Analysis. Alzheimer's and Dementia, 2016, 12, P789.	0.4	0
214	P2â€403: Targeting MCI with Cardiac Rehabilitation Exercise: A Feasibility Study. Alzheimer's and Dementia, 2016, 12, P799.	0.4	0
215	P3-181: Evaluating the Relationship Between Markers of Oxidative Stress and Cognitive Performance in Coronary Artery Disease Patients., 2016, 12, P889-P890.		0
216	P4-003: Designing a Randomized Placebo-Controlled Crossover Trial Investigating Nabilone as a Treatment for Agitation in Patients with Moderate-to-Severe Alzheimer's Disease. , 2016, 12, P1014-P1015.		0

#	Article	IF	CITATIONS
217	P4â€158: Omegaâ€3 Fatty Acids and Cognitive Performance in Coronary Artery Disease Patients: A Secondary Analysis of a Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial. Alzheimer's and Dementia, 2016, 12, P1075.	0.4	O
218	P4-329: Behavioural Neurology Assessment - Revised: Validation in Amnestic Mild Cognitive Impairment (AMCI)., 2016, 12, P1160-P1161.		0
219	O1â€13â€03: The Mild Behavioral Impairment Checklist (MBIâ€C): a New Rating Scale for Neuropsychiatric Symptoms as Early Manifestations of Neurodegenerative Disease. Alzheimer's and Dementia, 2016, 12, P209.	0.4	O
220	[P3â€"210]: PLASMA SPHINGOLIPID RATIOS AND VERBAL MEMORY PERFORMANCE IN A CORONARY ARTERY DISEASE POPULATION AT RISK FOR VASCULAR COGNITIVE IMPAIRMENT (VCI) AND ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1016.	0.4	0
221	[P3â€"239]: A LIPIDOMICS APPROACH TO ASSESS PLASMA SPHINGOLIPIDS AS PREDICTORS OF VERBAL MEMOR' PERFORMANCE IN CORONARY ARTERY DISEASE PATIENTS UNDERTAKING CARDIAC REHABILITATION: A C18:0 SIGNATURE FOR COGNITIVE RESPONSE TO EXERCISE. Alzheimer's and Dementia, 2017, 13, P1031.	Y 0.4	0
222	[P1â€"397]: A PROSPECTIVE OBSERVATIONAL STUDY INVESTIGATING CLINICAL RESPONSE TO CHOLINESTERASE INHIBITORS AND ASSOCIATION WITH CEREBRAL PERFUSION. Alzheimer's and Dementia, 2017, 13, P422.	0.4	0
223	How much can the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADASâ€Cog) tell us? Insights from a latent stateâ€trait autoâ€regressive (LSTâ€AR) model. Alzheimer's and Dementia, 2020, 16, e041582.	0.4	O
224	Angiotensin receptor blockers versus angiotensinâ€converting enzyme inhibitors: Longitudinal associations with PET amyloid in the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2020, 16, e042014.	0.4	0
225	Investigating the relationship between neuropsychiatric symptoms and cognition in mild cognitive impairment and Alzheimer's disease patients undergoing an exerciseâ€primed transcranial direct current stimulation clinical trial (The EXPRESS Study). Alzheimer's and Dementia, 2020, 16, e046158.	0.4	O
226	Does sex impact neuropsychiatric symptom burden in APOε4 carriers with atâ€risk cognitive conditions?. Alzheimer's and Dementia, 2020, 16, e047038.	0.4	0
227	Cerebrospinal fluid biomarkers in older adults with mild cognitive impairment, with and without a major depressive disorder. Alzheimer's and Dementia, 2020, 16, e047049.	0.4	0
228	Susceptibility to Undue Influence: The Role of the Medical Expert in Estate Litigation. Canadian Journal of Psychiatry, 2022, 67, 5-12.	0.9	0
229	Associations between the use of histamineâ€2 receptor antagonists vs. proton pump inhibitors and cognitive decline: A stratified longitudinal study in people with and without cognitive impairment. Alzheimer's and Dementia, 2021, 17, .	0.4	O
230	Leukotriene receptor antagonist use is associated with slower cognitive decline in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
231	Characterizing the phenomenology of anxiety in older adults with subjective cognitive decline. Alzheimer's and Dementia, $2021, 17, \ldots$	0.4	O
232	Distinct patterns of posterior default mode networkâ€medial temporal lobe connectivity in mild cognitive impairment and subjective cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	0
233	Lipid peroxidation mediates the relationship between cardiopulmonary fitness and depressive symptoms in people with coronary artery disease. Alzheimer's and Dementia, 2021, 17, .	0.4	О
234	Selfâ€report of seriousness of forgetting predicts objective memory ability in older adults with subjective cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	CITATIONS
235	The role of worry in subjective cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	0